glofitamab,Obinutuzumab 
roche
['dlbcl', 'glofitamab', 'lymphoma', 'genetech']
keep an eye on genetech's bite's. glofitamab is in phase 1 trial in r/r lymphomas. most were #dlbcl. orr 53.8% &amp; cr 57.1% in rp2d. . question is the dor and if there will be a need for re-dosing. 
Wanna-be immunologist. Tweets are my opinion only.